ArticleJACC. Advances2026
Artificial Intelligence-Driven Electrocardiogram Screening for Asymptomatic Left Ventricular Systolic Dysfunction in the General Population.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAsymptomatic left ventricular systolic dysfunction (LVSD) is a well-established precursor of overt heart failure (HF), yet it often remains undiagnosed in the general population. Artificial intelligence-enabled electrocardiogram (ECG) analysis offers a scalable approach for early detection.
objectivesThe purpose of this study was to evaluate the diagnostic performance of an artificial intelligence-enabled ECG model (AiTiALVSD) for identifying asymptomatic LVSD in a large health screening population.
methodsIn this retrospective, single-center study, we evaluated the AiTiALVSD model among 40,713 self-referred adults who underwent a total of 60,711 ECG-transthoracic echocardiography (TTE) pairs between 2011 and 2023. LVSD was defined as a left ventricular ejection fraction ≤40%. Model discrimination was assessed using the area under the receiver-operating characteristic curve (AUROC) and the area under the precision-recall curve (AUPRC), and diagnostic performance metrics were compared with established HF risk scores.
resultsAmong 60,711 ECG-TTE pairs, 32 cases (0.054%) met the criteria for LVSD. The AiTiALVSD model demonstrated excellent discrimination (AUROC 0.973; AUPRC 0.328), with a sensitivity of 90.6%, specificity of 99.4%, positive predictive value of 7.7%, and a negative predictive value of 100%. Established HF risk scores, including the MESA (Multi-Ethnic Study of Atherosclerosis) 5-year HF score and Pooled Cohort Equations to Prevent HF score, showed inferior discrimination (AUROC: 0.696 and 0.672, respectively). The MESA score was not designed to detect prevalent LVSD and was calculated without natriuretic peptide data, which may have disadvantaged its performance in this comparison. Simulation analyses suggested that approximately 1,841 ECGs and 13 confirmatory TTEs would be required to detect one case of LVSD.
conclusionsIn a real-world screening population with an extremely low prevalence of LVSD, the AiTiALVSD model demonstrated high diagnostic accuracy, supporting its potential role as a rule-out screening tool for HF prevention. Prospective validation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.